NewAmsterdam Pharma Company NV (NAMSW)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

Form 8-K - Current report

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements